StockData
Scinai Immunotherapeutics Ltd. logo

Scinai Immunotherapeutics Ltd. (SCNI) stock

SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 6/30
$0.37−0.01 (-1.40%)

Close on Nov 18, 2026Market cap $1.27MP/E –Yield –

Scinai Immunotherapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Scinai Immunotherapeutics's operating cash flow for the twelve months ending Dec 31, 2021 was -$7.43M. For fiscal 2025 it was -$6.03M. The highest annual figure on record is -$2.90M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$6.03M–
FY2024Dec 31, 2024-$6.34M–
FY2023Dec 31, 2023-$9.38M–
FY2022Dec 31, 2022-$7.27M–
FY2021Dec 31, 2021-$7.43M–
FY2020Dec 31, 2020-$22.56M–
FY2017Dec 31, 2017-$2.90M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2023Jun 30, 2023-$2.88M–
Q1 FY2023Mar 31, 2023-$3.06M–
Q2 FY2022Jun 30, 2022-$3.67M–
Q1 FY2022Mar 31, 2022-$1.11M–
Q4 FY2021Dec 31, 2021-$1.86M–

More Scinai Immunotherapeutics figures

See a number that looks wrong?